David Olmos

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
    Sarcoma 2011:402508. 2011
  2. doi request reprint Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
    Cancer J 16:183-94. 2010
  3. doi request reprint Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
  4. doi request reprint Oncocytic adrenal cortical carcinosarcoma with pleomorphic rhabdomyosarcomatous metastases
    Khin Thway
    Sarcoma Unit, Department of Histopathology, The Royal Marsden NHS Foundation Trust, London, UK
    Am J Surg Pathol 36:470-7. 2012
  5. doi request reprint Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
    Robin L Jones
    Royal Marsden Hospital, London, SW3 6JJ, UK
    Cancer Chemother Pharmacol 68:423-9. 2011
  6. doi request reprint Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors
    Khin Thway
    Sarcoma Unit, Department of Histopathology, Drug Development and Medical Oncology Units, The Royal Marsden NHS Foundation Trust, London, UK
    Am J Surg Pathol 36:462-9. 2012
  7. doi request reprint Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Lancet Oncol 13:1114-24. 2012

Detail Information

Publications7

  1. pmc Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
    Sarcoma 2011:402508. 2011
    ..Despite, the initial promising results, not all patients benefit from IGF-1R inhibition, and consequently, there is an urgent need for the identification of predictive markers of response...
  2. doi request reprint Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside
    David Olmos
    Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
    Cancer J 16:183-94. 2010
    ..Despite these encouraging results, not all patients benefit from IGF-1R inhibition and consequently there is an urgent need for the identification of predictive markers of response...
  3. doi request reprint Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
    ..The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcoma patients treated with chemotherapy at a single referral center...
  4. doi request reprint Oncocytic adrenal cortical carcinosarcoma with pleomorphic rhabdomyosarcomatous metastases
    Khin Thway
    Sarcoma Unit, Department of Histopathology, The Royal Marsden NHS Foundation Trust, London, UK
    Am J Surg Pathol 36:470-7. 2012
    ..Here, we discuss the clinical, radiologic, and pathologic findings and review the literature on adrenal cortical carcinosarcomas...
  5. doi request reprint Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
    Robin L Jones
    Royal Marsden Hospital, London, SW3 6JJ, UK
    Cancer Chemother Pharmacol 68:423-9. 2011
    ..The aim of this study was to evaluate the clinical benefit for sarcoma patients treated within the Phase I Unit of a single referral centre...
  6. doi request reprint Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors
    Khin Thway
    Sarcoma Unit, Department of Histopathology, Drug Development and Medical Oncology Units, The Royal Marsden NHS Foundation Trust, London, UK
    Am J Surg Pathol 36:462-9. 2012
    ..p16 was the most sensitive and specific marker for detecting WDL/DDL, and the combination of CDK4 and p16 is of more discriminatory value than the combination of either with MDM2, the least sensitive and specific of the 3 markers...
  7. doi request reprint Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Lancet Oncol 13:1114-24. 2012
    ..We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome...